These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7992710)

  • 21. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
    Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
    Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of renal pelvic cancer with recurrence of liver metastasis showing partial response by injection of methotrexate and intraarterial infusion of cisplatin and pirarubicin].
    Tsuya H; Hato T; Murase K; Sato T; Kaneda N; Takahashi C; Takeuchi T; Shimokawa K
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1079-81. PubMed ID: 9644324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radiotherapy in treatment of relapsing renal cell cancer].
    Metelev VV; Zharinov GM
    Vopr Onkol; 2008; 54(6):775-7. PubMed ID: 19241859
    [No Abstract]   [Full Text] [Related]  

  • 26. [Intra-arterial chemotherapy in urological cancer].
    Mitsumori K; Sato K; Kato T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):197-203. PubMed ID: 11865624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemotherapy of renal cell carcinoma. 2. Combined chemotherapy using ACNU and VBL].
    Kobayashi M; Imai K; Nakai K; Kumasaka F; Suzuki T; Ito Y; Yamanaka H; Sugihara S
    Hinyokika Kiyo; 1986 Mar; 32(3):375-83. PubMed ID: 3460318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
    Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX; Ogawa O; Kakehi Y
    Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Usefulness of magnetic resonance imaging for evaluation of therapeutic efficacy of bone metastases from bladder cancer: a case report].
    Urushibara M; Tsukamoto T; Horiuchi S; Negishi T
    Hinyokika Kiyo; 1998 Jul; 44(7):501-3. PubMed ID: 9752607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
    Chapman AE; Goldstein LJ
    Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
    [No Abstract]   [Full Text] [Related]  

  • 36. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
    Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
    J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey of chemotherapy of metastatic renal cancer.
    Kühböck J
    Semin Surg Oncol; 1988; 4(2):87-90. PubMed ID: 3293155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of bone metastases from advanced renal cell carcinoma.
    Khattak MA; Martin HL
    Eur J Cancer; 2012 Nov; 48(16):3123-5. PubMed ID: 22682018
    [No Abstract]   [Full Text] [Related]  

  • 40. Cocktail modulator mixtures for overcoming multidrug resistance in renal cell carcinoma.
    Yu DS; Sun GH; Ma CP; Chang SY
    Urology; 1999 Aug; 54(2):377-81. PubMed ID: 10443744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.